News|Articles|February 13, 2025
Executive Summary: Addressing Regulatory Requirements for CRISPR sgRNA Purity with Orthogonal Chromatography
Author(s)Agilent
The increasing demand for high-purity, regulatory-compliant guide RNA (gRNA) manufacturing in the CRISPR gene editing market underscores the need for advanced production capabilities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
2
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
3
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
4
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
5
